Evidence map›Paper›PMID 39276859›Full record

ArticleThe ocular surface2024

Epidemiology and risk factors for the development of cicatrizing conjunctivitis in chronic ocular graft-versus-host disease.

Nicole B Kantor, Paula A Sepulveda-Beltran, David Valdés-Arias, Elyana V T Locatelli, Lakshman Mulpuri, Araliya N Gunawardene, Guillermo Amescua, Victor L Perez, Rahul Tonk, Trent Wang and 1 more

Abstract read
In one paragraph

Article in The ocular surface, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Nicole B KantorBascom Palmer Eye Institute, Department of Ophthalmology, University of Miami Miller School of Medicine, Miami, FL, 33136, USA; Surgical and Research Services, Miami Veterans Administration Medical Center, 1201 NW 16th St, Miami, FL, 33125, USA.
Paula A Sepulveda-BeltranBascom Palmer Eye Institute, Department of Ophthalmology, University of Miami Miller School of Medicine, Miami, FL, 33136, USA; Surgical and Research Services, Miami Veterans Administration Medical Center, 1201 NW 16th St, Miami, FL, 33125, USA.
David Valdés-AriasBascom Palmer Eye Institute, Department of Ophthalmology, University of Miami Miller School of Medicine, Miami, FL, 33136, USA; Surgical and Research Services, Miami Veterans Administration Medical Center, 1201 NW 16th St, Miami, FL, 33125, USA.
Elyana V T LocatelliBascom Palmer Eye Institute, Department of Ophthalmology, University of Miami Miller School of Medicine, Miami, FL, 33136, USA; Surgical and Research Services, Miami Veterans Administration Medical Center, 1201 NW 16th St, Miami, FL, 33125, USA.
Lakshman MulpuriBascom Palmer Eye Institute, Department of Ophthalmology, University of Miami Miller School of Medicine, Miami, FL, 33136, USA.
Araliya N GunawardeneSurgical and Research Services, Miami Veterans Administration Medical Center, 1201 NW 16th St, Miami, FL, 33125, USA.
Guillermo AmescuaBascom Palmer Eye Institute, Department of Ophthalmology, University of Miami Miller School of Medicine, Miami, FL, 33136, USA.
Victor L PerezBascom Palmer Eye Institute, Department of Ophthalmology, University of Miami Miller School of Medicine, Miami, FL, 33136, USA.
Rahul TonkBascom Palmer Eye Institute, Department of Ophthalmology, University of Miami Miller School of Medicine, Miami, FL, 33136, USA.
Trent WangSylvester Comprehensive Cancer Center, Division of Transplant and Cell Therapy, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA.
Anat GalorBascom Palmer Eye Institute, Department of Ophthalmology, University of Miami Miller School of Medicine, Miami, FL, 33136, USA; Surgical and Research Services, Miami Veterans Administration Medical Center, 1201 NW 16th St, Miami, FL, 33125, USA. Electronic address: agalor@med.miami.edu.

Funding

Shared Equipment ModuleP30EY014801 · NEI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Abigail S Hackam · 2004 to 2026
$12.2M
Immune Mechanisms in Ocular Graft versus Host DiseaseR01EY024484 · NEI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI LEVY, ROBERT BENJAMIN, PEREZ, VICTOR L · 2014 to 2025
$5.1M
Defining bacterial members of the ocular surface microbiome and assessing stability over timeU24EY035102 · NEI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI GALOR, ANAT, ST LEGER, ANTHONY J · 2023 to 2025
$3.3M
Tear protein biomarkers of refractive surgery painR33EY032468 · NEI · OREGON HEALTH & SCIENCE UNIVERSITY · PI AICHER, SUE A, GALOR, ANAT · 2023 to 2025
$2.9M
Dry Eye and MicroenvironmentR01EY026174 · NEI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI GALOR, ANAT, KUMAR, NARESH · 2016 to 2020
$1.9M
A pilot study of the safety and feasibility of transcutaneous electrical nerve stimulation (TENS) for chronic ocular painI21RX003883 · VA · MIAMI VA HEALTH CARE SYSTEM · PI FELIX, ELIZABETH ROY · 2022 to 2023
–
Eye Pain and Photophobia: Ocular Signs and Symptoms As Markers of Central Abnormalities in Gulf War IllnessI01CX002633 · VA · MIAMI VA HEALTH CARE SYSTEM · PI Anat Galor · 2024 to 2026
–
Neural mechanisms underlying photophobia and dry eyeI01CX002015 · VA · MIAMI VA HEALTH CARE SYSTEM · PI Anat Galor · 2020 to 2026
–
Lipid mediators and their signaling in ocular surface inflammation and meibomian gland dysfunctionI01BX004893 · VA · MIAMI VA HEALTH CARE SYSTEM · PI GALOR, ANAT, MANDAL, NAWAJES · 2021 to 2025
–
BLRD VA I01 BX004893CSRD VA I01 CX002015CSRD VA I01 CX002633NEI NIH HHS P30 EY014801NEI NIH HHS R01 EY024484NEI NIH HHS R01 EY026174NEI NIH HHS R33 EY032468NEI NIH HHS U24 EY035102RRD VA I21 RX003883
6 · The paper itself

Abstract

purposeTo evaluate the incidence of chronic cicatrizing conjunctivitis (CCC) and its associated risk factors in the context of chronic ocular graft-vs-host disease (coGVHD).

methodsA retrospective chart review of individuals diagnosed with coGVHD following hematopoietic stem cell transplantation (HSCT) who were seen at the Bascom Palmer Eye Institute between May 2010 and November 2021 was performed. Data regarding baseline demographic characteristics, systemic co-morbidities, lid margin abnormalities, ocular cicatricial changes, transplant information, immunosuppressive therapy, and GVHD severity assessments were collected. The incidence of cicatricial conjunctivitis was estimated with Kaplan-Meier survival analysis. A Cox regression model was used to assess the contribution of demographic and systemic variables to the development of CCC.

results167 individuals were included (53.9 ± 14.7 years old; 60.5 % male). 65 individuals presented with features suggestive of CCC an average of 60.9 ± 53.8 months after HSCT, with 60-month and 120-month incidences of 29.3 % and 48.9 %, respectively. Multivariable analysis demonstrated that age younger than 50 at the time of the first eye visit was associated with a higher chance of CCC development (Hazard Ratio (HR): 2.14, 95 % Confidence Interval (CI): 1.16-3.97, p = 0.02).

conclusionClinically detected cicatrizing conjunctivitis is an ocular manifestation of coGVHD, with an incidence that increases over time. Younger individuals may be at higher risk for CCC development.

Indexed as

CicatrixConjunctivitisGraft vs Host DiseaseHematopoietic Stem Cell TransplantationAdultAgedChronic DiseaseFemaleHumansIncidenceMaleMiddle AgedRetrospective StudiesRisk FactorsAllogeneic hematopoietic stem cell transplantCicatrizing conjunctivitisConjunctival fibrosisGraft versus host diseaseImmune-mediated ocular disordersImmunopathologyOcular graft versus host diseaseOcular surface disease

Identifiers

PMID39276859
PMCPMC11625611

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.